EUSA Pharma (UK) Ltd.

Ligand Pharmaceuticals, Inc. has made its second major oncology investment in two months with the acquisition of Apeiron Biologics AG and the Austrian biotech’s royalty rights for Qarziba (dinutuxi

Essential Pharma is best known as a generics player but the acquisition of fellow UK biotech Renaissance Pharma and its mid-stage immunotherapy for a rare type of childhood cancer shows the firm's

China’s public healthcare service payer, the National Healthcare Security Administration (NHSA), kept the level of drug price cuts steady at an average of roughly 60% in its latest round of annual neg

Recordati SpA will acquire EUSA Pharma Ltd. in a €750m ($847m) deal, marking a foray into rare cancers for the Italian firm. The deal is “an excellent opportunity to further expand and reinforce ou